Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 220

Posts Tagged ‘disorder’

Global Hypopigmentation Disorder Treatment Market Analysis & Trends

Posted by fidest press agency su mercoledì, 1 gennaio 2020

This report analyzes the current and future scenario of the global hypopigmentation disorder treatment market. Increase in patient population with hypopigmentation disorders, growth of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be the major drivers of the global market during the forecast period.The global hypopigmentation disorder treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hypopigmentation disorder treatment market.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder

Posted by fidest press agency su lunedì, 23 dicembre 2019

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved SPRAVATO (esketamine) nasal spray, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), for adults living with treatment-resistant major depressive disorder (TRD). According to the approval, patients are considered to have TRD if they have not responded to at least two different treatments with antidepressants in the current moderate-to-severe depressive episode. Major depressive disorder (MDD) affects approximately 40 million people across Europeand is the leading cause of disability worldwide.2,3 For these patients, the main goal of treatment is to relieve the symptoms of depression, and ultimately achieve remission, with few, if any, symptoms of depression remaining.4 However, about one third of patients with MDD do not respond to currently available treatments.5The approval of esketamine is based on data from a clinical trial programme in patients with TRD, including over 1,600 patients treated with esketamine. The five Phase 3 trials included three short-term studies, one randomised withdrawal and maintenance of effect study, and one long-term safety study.6,7,8,9,10* These data demonstrated that treatment with esketamine nasal spray plus a newly initiated oral antidepressant was associated with a greater reduction in depressive symptoms compared to a newly initiated oral antidepressant plus placebo nasal spray, in adult patients (18-64 years), with the onset of efficacy as early as Day 2.6 Approximately 70 percent of esketamine-treated patients responded to treatment, with a ≥50 percent symptom reduction. Furthermore, approximately half of all treated patients achieved remission at the end of the 4 week studies.1 Continued treatment with esketamine nasal spray plus oral antidepressant reduced the risk of relapse by 70 percent among patients with stable response and by 51 percent in patients in stable remission, compared to continuing treatment with oral antidepressant alone.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Psilocybin program for major depressive disorder

Posted by fidest press agency su martedì, 26 novembre 2019

Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatment of major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD.The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges both the unmet medical need in this broad population and the potential for significant improvements over existing therapies, and bolsters Usona’s mission to advance this revolutionary treatment paradigm toward new drug approval.“The results from previous studies clearly demonstrate the remarkable potential for psilocybin as a treatment in MDD patients, which Usona is now seeking to confirm in its own clinical trials. What is truly groundbreaking is FDA’s rightful acknowledgement that MDD, not just the much smaller treatment-resistant depression population, represents an unmet medical need and that the available data suggest that psilocybin may offer a substantial clinical improvement over existing therapies,” says Charles Raison, MD, Director of Clinical and Translational Research at Usona. “Given that there is so much complexity with psilocybin and that Usona is charting new ground, these interactions will ensure that Usona and the FDA are aligned in approaching the development program with acceptable best practices.” The new status follows the recent launch of Usona’s Phase 2 clinical trial, PSIL201, which will include approximately 80 participants at seven study sites around the US. Two of the seven study sites are currently recruiting, with the others expected to be active by the first quarter of 2020.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Quadrant Biosciences to Collaborate on Signature Study of Minocycline Treatment of Autism Spectrum Disorder

Posted by fidest press agency su sabato, 27 ottobre 2018

Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network (ATN) and its university research partners on research into the treatment of autism spectrum disorder (ASD). The ATN is a collaboration of Autism Speaks and some of the finest children’s hospitals and academic institutions in North America, specializing in multi-disciplinary medical care for children with autism. This Signature Study, including researchers from the Cincinnati Children’s Hospital Medical Center, University of Pittsburgh, and University of Missouri, is looking at the treatment of autism symptoms with the antibiotic minocycline. In addition to providing financial support for this important study, Quadrant Biosciences will be collecting salivary RNA data to further its work on epigenetic factors associated with ASD.Prompted by earlier studies, researchers at the Cincinnati Children’s Hospital Medical Center initiated a study looking at the effects of minocycline treatment on ASD symptoms.
Given these characteristics, animal researchers hypothesized that minocycline treatment would improve autism symptoms, and indeed this was the case. Researchers saw improvement in many classic autism symptoms such as aberrant social interaction, exploratory behavior, locomotion, and anxiety behaviors in various mouse models of ASD treated with minocycline. Additionally, trials in humans with Fragile X Syndrome-associated ASD have demonstrated improvement on the Clinical Global Impression Improvement subscale. These compelling results prompted the initiation of the present Autism Speaks ATN Signature Study.
The Autism Speaks ATN research also received support through the ATN’s role as the federally funded Autism Intervention Research Network for Physical Health. The clinical trial to begin later this year will involve a 24-subject, double-blind, placebo-controlled, four-week crossover study of minocycline in youths with ASD ages 12 to 22 years. The study aims to: 1) Determine if minocycline use will be associated with reduction in elevated EEG gamma power in persons with ASD compared to placebo; 2) assess the short-term safety and tolerability of minocycline in youths with ASD; and 3) better understand the efficacy and dosage of minocycline for the short-term treatment of memory, social gaze, psychophysical markers, attentional impairments, quality of life, and other concerns in adolescents with ASD.
The study includes well-regarded researchers in the autism field including Craig A. Erickson, M.D., Professor, Division of Child and Adolescent Psychiatry, and Logan Wink, Associate Professor, Cincinnati Children’s Hospital Medical Center; David Beversdorf, M.D., Professor of Neurology, Radiology, and Psychology, Thompson Center for Autism & Neurodevelopmental Disorders, University of Missouri; and Benjamin Handen, Ph.D., Professor of Psychiatry, Pediatrics, Psychology, and Education, University of Pittsburgh.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Ilana Manolson: Untitled

Posted by fidest press agency su domenica, 31 maggio 2009

untitleNew York Jason McCoy Inc. 41 East 57th Street until 24/7/2009 Jason McCoy Gallery is pleased to present an exhibition of paintings by the Boston based artist Ilana Manolson. This will be the first New York solo exhibition for the artist. Ilana Manolson paints momentary impressions of nature as they unfold through the various seasons. Combining realist elements with fields of color abstraction, she depicts her subject on the verge of change and as it swings its pendulum between order and disorder. Having begun her career as a printmaker, who was used to adding “whites” through the omission of color, Manolson’s painting technique adds an interesting twist. Whereas traditionally a painter adds the lightest colors last, Manolson builds up paint to add highlights, but then employs a selection of spatulas and scrapers to “pull from the paint” and reveal the light that hides underneath it. Manolson is a former naturalist, whose work in a Canadian national park entailed the constant study of 12-inch squares of grazing land in order to assess the condition of the land at large. This experience has left her well equipped for the quest to transform microscopic details into representative images of the macrocosm. Here, changes of light and color or the illusive reflections found in water and sky, for example all become contemplations of transience and transformation, and Manolson adds: “Enter this painted place that creates its own logic: its order and rhythms; its contradictions and surprises. In these paintings we are part of an endless story of cycles -of seasons where in the comfort of repetition there is always something new…. Look down at your feet and you will see power in every neglected corner.” Ilana Manolson has exhibited extensively in the United States. She is a recent recipient of the Mass Cultural Council Grant (2008). Her works are in the permanent collections of the Museum of Fine Arts, Boston, the De Cordova Museum, Lincoln, the Boston Public Library, the Ballinglen Arts Foundation, JP Morgan & Company, New York; Sanford Bernstein & Sons, New York, and Citizens Bank, Providence, Rhode Island, among others. She lives and works in Boston. (image untitle)

Posted in Estero/world news, Mostre - Spettacoli/Exhibitions – Theatre | Contrassegnato da tag: , , , | Leave a Comment »